Lawyers and Settlements
Home Page >> Anti-coagulation medications >> Articles

Anit-Coagulation Medicine Articles

Xarelto Bellwether Score is 3-1 for the Defendants: MDL to Map out Strategy

Xarelto Bellwether Score is 3-1 for the Defendants: MDL to Map out Strategy January 7, 2018. By Gordon Gibb.
New Orleans, LA:With three federal bellwether cases having gone to the defendant and a fourth in state court favoring the plaintiff, the judge heading up the 18,500 consolidated cases in federal court has signaled he is looking for guidance from the various parties involved, with oral arguments on the docket for the end of the month following a status report. The Xarelto Lawsuit MDL is under the guidance and management of US District Judge Eldon Fallon in US District Court, Eastern District of Louisiana.
Read [ Xarelto Bellwether Score is 3-1 for the Defendants: MDL to Map out Strategy ]

$27.8 Million Xarelto Plaintiff Verdict Could be Tossed Out

$27.8 Million Xarelto Plaintiff Verdict Could be Tossed Out December 20, 2017. By Gordon Gibb.
Philadelphia, PA: A verdict in favor of the plaintiff in a bellwether Xarelto lawsuit may be all for naught if the defense team for co-defendants Janssen Pharmaceuticals Inc. and Bayer AG are successful in having the verdict tossed.
Read [ $27.8 Million Xarelto Plaintiff Verdict Could be Tossed Out ]

$28M Xarelto Verdict Against J&J and Bayer

$28M Xarelto Verdict Against J&J and Bayer December 5, 2017. By Lucy Campbell.
Philadelphia, PA: A jury has found against units of Johnson & Johnson (J&J) and Bayer AG in the fourth bellwether Xarelto (Rivaroxaban) case being heard as part of a Xarelto mass tort. The award, nearly $28 million, is the first favoring a plaintiff, in this case Lynn Hartman, who alleged she suffered a serious gastrointestinal bleed while using the blood thinning medication. The jury found that the pharmaceutical companies failed to provide adequate warnings regarding the risks for bleeding associated with Xarelto.
Read [ $28M Xarelto Verdict Against J&J and Bayer ]

Is it Getting Just a Bit Harder to Bring an Eliquis Lawsuit?

Is it Getting Just a Bit Harder to Bring an Eliquis Lawsuit? November 18, 2017. By Gordon Gibb.
Manhattan, NY: A new study that appears to deflect some heat away from Eliquis bleeding risks, combines with a previous court decision by a federal judge back in May to intensify the challenge involved in bringing a successful Eliquis lawsuit.
Read [ Is it Getting Just a Bit Harder to Bring an Eliquis Lawsuit? ]

Trial for First Philadelphia Mass Tort Xarelto Lawsuit Finally Underway

Trial for First Philadelphia Mass Tort Xarelto Lawsuit Finally Underway November 17, 2017. By Gordon Gibb.
Philadelphia, PA: The first trial in the large Xarelto mass tort in Philadelphia is underway, with damning testimony already on the record from a former commissioner of the US Food and Drug Administration (FDA). While three bellwether lawsuits have already been tried in multidistrict litigation in Louisiana, the Xarelto lawsuit brought by plaintiff Lynn Hartman is the first of some 1,500 cases housed in the Philadelphia mass tort to face a jury.
Read [ Trial for First Philadelphia Mass Tort Xarelto Lawsuit Finally Underway ]

First Xarelto Trial Stalled Over Allegations of Witness Tampering

First Xarelto Trial Stalled Over Allegations of Witness Tampering November 6, 2017. By Lucy Campbell.
Philadelphia, PA: Allegations of witness tampering have stalled the beginning of the Xarelto litigation. The first Xarelto trail was set to being Monday, November 6, but instead got sidelined by attempts to determine the significance of a meeting between a key witness, Dr. Timothy Aldridge, the plaintiff’s treating physician, and a Janssen sales representative.
Read [ First Xarelto Trial Stalled Over Allegations of Witness Tampering ]

As Eliquis Lawsuits Fall, New Study Heightens Bleeding Risk in Eliquis Class

As Eliquis Lawsuits Fall, New Study Heightens Bleeding Risk in Eliquis Class October 17, 2017. By Gordon Gibb.
Manhattan, NY: A new study released earlier this month suggests that blood thinners in the non-vitamin K oral anticoagulant class, or NOACs, could see heightened risk of bleeding when the blood thinners are taken in combination with certain drugs. Amongst the drugs in the so-called NOAC class is Eliquis, a new-age blood thinner that has been the subject of many an Eliquis lawsuit alleging unnecessary bleeding risk.
Read [ As Eliquis Lawsuits Fall, New Study Heightens Bleeding Risk in Eliquis Class ]

Xarelto Seeking FDA Approval for Lower Dosage While Litigation Posturing Continues

Xarelto Seeking FDA Approval for Lower Dosage While Litigation Posturing Continues August 5, 2017. By Gordon Gibb.
Washington, DC: Towards the end of May plaintiffs embroiled in some 18,000 Xarelto lawsuits consolidated in multidistrict litigation were pushing back against a move by defendants Janssen Pharmaceuticals Inc. (Janssen, a division of Johnson & Johnson) and Bayer HealthCare Pharmaceuticals Inc. (Bayer) to escape claims that relied on allegations plaintiffs had previously dropped.
Read [ Xarelto Seeking FDA Approval for Lower Dosage While Litigation Posturing Continues ]

Eliquis Lawsuit Alleges Wrongful Death, Product Misrepresentation

Eliquis Lawsuit Alleges Wrongful Death, Product Misrepresentation July 16, 2017. By Gordon Gibb.
New York, NY: Raymond Warme, according to a recent Eliquis lawsuit, was prescribed the new-age blood thinner apixaban for atrial fibrillation. That was in April, 2014. Litigation brought on his behalf by his daughter and partner claim that Warme began to experience gastrointestinal bleeding within two months of starting on the drug. He would not survive.
Read [ Eliquis Lawsuit Alleges Wrongful Death, Product Misrepresentation ]

Second Bellwether Xarelto Lawsuit Goes to Defendant, All Eyes on Third

Second Bellwether Xarelto Lawsuit Goes to Defendant, All Eyes on Third July 8, 2017. By Gordon Gibb.
New Orleans, LA: The second bellwether Xarelto lawsuit in multidistrict litigation over allegations of Xarelto bleedout in association with the new age blood thinner has gone, like the first, to the defendant. While this may prove disappointing to litigants alleging the anticoagulant is unsafe, there are still two more bellwether trials to roll out later this year, with some 15,000 cases in the federal multidistrict litigation pipeline housed in New Orleans. Additional cases are percolating at the state level in Philadelphia.
Read [ Second Bellwether Xarelto Lawsuit Goes to Defendant, All Eyes on Third ]

Page: 1  2  3     Next»